Court Place Advisors LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,763 shares of the company’s stock after selling 280 shares during the period. Court Place Advisors LLC’s holdings in Johnson & Johnson were worth $2,278,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Rather & Kittrell Inc. increased its holdings in Johnson & Johnson by 2.0% during the 2nd quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after acquiring an additional 58 shares in the last quarter. Wagner Wealth Management LLC increased its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after acquiring an additional 59 shares in the last quarter. MTM Investment Management LLC increased its holdings in Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after acquiring an additional 61 shares in the last quarter. OneAscent Financial Services LLC grew its holdings in shares of Johnson & Johnson by 3.3% during the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after buying an additional 63 shares in the last quarter. Finally, Beech Hill Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after buying an additional 63 shares in the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $145.60 on Monday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $158.90 and a 200-day moving average of $161.94. The firm has a market cap of $378.41 billion, a price-to-earnings ratio of 10.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.55.
Johnson & Johnson Dividend Announcement
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Raymond James lowered their price target on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Atlantic Securities lifted their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. Finally, TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.
Check Out Our Latest Analysis on JNJ
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Investing in Construction Stocks
- Is domestic travel back on track? Check out these companies
- What is an Earnings Surprise?
- MarketBeat Week in Review – 10/23 – 10/27
- How to Invest in Social Media
- Can casino stocks win big if economy slows?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
